Alpha-9 Oncology is a clinical-stage radiopharmaceutical company engineering bespoke, tumor-targeting molecules that deliver alpha- and beta-emitting isotopes directly to cancer cells while sparing healthy tissue. Spun out of the University of British Columbia and BC Cancer in 2019 and now headquartered in Boston with research operations in Vancouver, the company iteratively optimizes each part of a radiopharmaceutical - binder, linker, chelator and radioisotope - to build a pipeline of paired imaging and therapy candidates. Backed by $258M in total funding, including a $175M Series C in 2024, Alpha-9 aims to expand precision radiotherapy across validated oncology targets.
Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.
Paul Blanchfield is the CEO of Alpha-9 Oncology, a Boston-based clinical-stage radiopharmaceutical company developing targeted alpha and beta therapies for cancer. He took the top job in November 2025 after running Lantheus as President, following earlier operator stints at Takeda and Shire and a five-year run at McKinsey.
Convergent Therapeutics is a clinical-stage biotechnology company in Cambridge, Massachusetts developing next-generation targeted radiotherapies for cancer. Its lead candidate, CONV01-α, is a PSMA-targeted monoclonal antibody linked to the alpha-emitting radioisotope actinium-225, designed to deliver tumor-killing radiation to metastatic castration-resistant prostate cancer while sparing healthy tissue. The technology, pioneered in the lab of PSMA-targeting pioneer Dr. Neil Bander and licensed from Cornell University, is led by oncologist Dr. Philip Kantoff.
Philip Kantoff is a medical oncologist who spent three decades shaping how the world treats prostate cancer, then walked away from running medicine at one of the country's largest cancer hospitals to start a company. As co-founder and CEO of Convergent Therapeutics in Cambridge, Massachusetts, he is developing CONV01-alpha, an alpha-emitting radioantibody that hunts down prostate tumor cells and irradiates them at close range. He has published more than 500 papers, been cited over 85,000 times, mentored a generation of oncology leaders, and at an age when most peers retire, raised $90 million in Series A funding to bring a new class of cancer therapy into the clinic.
Ratio Therapeutics is a Boston-based clinical-stage biotech engineering next-generation targeted radiopharmaceuticals for solid tumors. Its proprietary Trillium and Macropa platforms tune how radioactive cancer-killing payloads travel through the body, aiming to deliver a lethal dose to tumors while sparing healthy tissue. Backed by major pharma partners including Novartis, Bayer, Lantheus and Bristol Myers Squibb, Ratio is advancing FAP- and SSTR2-targeted programs from imaging into therapy.